Iatrogenic Cushing's Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibitors: Six Cases

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4394-4398

  Samaras, Katherine ^a,f   Pett, Sarah ^b,c   Gowers, Andrew ^d   McMurchie, Marilyn ^e   Cooper, David A ^b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b St Vincent's Hospital   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Holdsworth House General Practice   (Australia)

^e 407 Doctors General Practice ^*  (Australia)

^f GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOCHROME P450; FLUTICASONE; HYDROCORTISONE; PROTEINASE INHIBITOR; RITONAVIR;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADRENAL SUPPRESSION; ADULT; ASTHMA; BODY COMPOSITION; CLINICAL ARTICLE; CONFERENCE PAPER; CRUSH TRAUMA; CUSHING SYNDROME; DISEASE EXACERBATION; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCORTISOLISM; LIPODYSTROPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL INSUFFICIENCY; ADULT; ANDROSTADIENES; CUSHING SYNDROME; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RITONAVIR;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 23044467452     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0036     Document Type: Conference Paper

References (17)

1. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV 2002 Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137(Pt 2):381-433
2. Zeldin RK, Petruschke RA 2004 Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. Antimicrob Chemother 53:4-9
3. Williams SG, Schmidt DK, Redd SC, Storms W 2003 National Asthma Education and Prevention Program. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 52:1-8
4. Mollmann H, Wagner M, Meibohm B, Hochhaus G, Barth J, Stockmann R, Krieg M, Weisser H, Falcoz C, Derendorf H 1998 Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 53:459-467
5. Seretide product information 2003 GlaxoSmithKline Australia Pty Ltd. Sydney, New South Wales, Australia
6. Lipworth B 1999 Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 159:941-955
7. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR 1999 Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 75:274
8. Findlay CA, Macdonald JF, Wallace AM, Geddes N, Donaldson MD 1998 Lesson of the week: childhood Cushing's syndrome induced by betamethasone nose drops and repeat prescriptions. BMJ 317:739-740
9. Mollmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, Daley-Yates PT, Krieg M, Stockmann R, Barth J, Lawlor C, Mollmann AC, Derendorf H, HochhausG2001 Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol. 41:1329-1338
10. Gupta SK, Dube MP 2002 Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy. Clin Infect Dis 35:e69-e71
11. Hillebrand-Haverkort ME, Prummel MF, Ten Veen JH 1999 Ritonavir-induced Cushing's syndrome in a patient treated with nasal fluticasone. AIDS 13:1803
12. Rouanet I, Peyriere H, Mauboussin JM, Vincent D 2003 Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone. HIV Med 4:149-150
13. Clevenbergh P, Corcostegui M, Gerard D, Hieronimus S, Mondain V, Chichmanian RM, Sadoul JL, Dellamonica P 2002 Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect 44:194-195
14. Kannisto S, Laatikainen A, Taivainen A, Savolainen K, Tukiainen H, Voutilainen R 2004 Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression during inhaled steroid therapy in adult asthmatic patients. Eur J Endocrinol 150:687-690
15. Schambelan M, Benson CA, Carr A Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS 2002 International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J AIDS 31:257-275
16. Ingelman-Sundberg M 2004 Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:89-104
17. Wilson AM, Blumsohn A, Jung RT, Lipworth BJ 2000 Asthma and Cushing's syndrome. Chest 117:593-594